JPRN-C000000443已完成1 期
Phase I/II study of the combination of Oxaliplatin and S-1 in patients with advanced/recurrent colorectal cancer - SOX
Outpatient Oncology Unit Kyoto University Hospital0 个研究点目标入组 42 人开始时间: 2006年7月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) during flucytosine medication 2) Active infection or inflammation 3) Uncontrolled severe Diabtes 4) patient severe medical condition 5) patient with interstitial pneumonitis or the history 6) patient with active gastrointestinal bleeding 7) patient with severe neurotoxicity 8) patient with active chicken pox 9) patient with metastasis of CNS 10) patient with other concurrent malignancy affecting on survival or adverse events 11) pregnant or nursing patient or with intent to bear baby 12) patient with allergic history to drug 13) patient with massive effusion of massive ascites 14) patient evaluated to be inadequate by a attending doctor
研究者
相似试验
进行中（未招募）
不适用
Phase I/II study of oxaliplatin combined with melphalan in isolated hepatic perfusion for the treatment of liver metastases. - Oxaliplatin combined with melphalan in IHP.EUCTR2006-005088-25-NLeiden University Medical Center
尚未招募
不适用
Phase I/II study of oxaliplatin combined with melphalan in isolated hepatic perfusion for the treatment of liver metastases.liver metastasessecondary liver tumours10017991NL-OMON30309eids Universitair Medisch Centrum60
进行中（未招募）
不适用
A randomized phase II study of oxaliplatin and capecitabine combination vs irinotecan and capecitabine combination for the treatment of elderly patients with advanced colorectal cancer.EUCTR2004-001159-12-ITAZIENDA OSPEDALIERA S. CARLO
已完成
3 期
A randomized phase III study of oxaliplatin based chemotherapy versus combination chemotherapy of TS-1,irinotecan and bevacizumab as first line therapy for unresectable or recurrent colorectal cancerJPRN-UMIN000007834The Tokyo Cooperative Oncology Group450
未知
2 期
Phase II clinical study on combination of oxaliplatin (L-OHP) and S-1 in advanced / recurrent gastric cancer untreated with chemotherapyGastric cancerJPRN-jRCT2080220365Yakult Honsha Co.,Ltd.